Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer (BMC Cancer, (2024), 24, 1, (16), 10.1186/s12885-023-11783-5)

Following publication of the original article [1], the authors reported an error in the affiliations of authors Başak Oyan, Özlem Sönmez, Leyla Özer, Ali Arıcan, Özlem Er and Mustafa Bozkurt. These authors are all affiliated to institution 2.

Keywords

Colon Cancer , Fluouracil , Rechallenge , Regorafenib , Survival , Third-Line Treatment

Journal or Series

BMC Cancer

Scopus Q Value

Q1

Volume

24

Issue

1

Citation

Şenocak Taşçı, E., Oyan, B., Sönmez, Ö., Mutlu, A. U., Atcı, M. M., Sakin, A. ... Bozkurt, M. (2024). Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer (BMC Cancer, (2024), 24, 1, (16), 10.1186/s12885-023-11783-5). BMC Cancer, 24(1). https://dx.doi.org/10.1186/s12885-024-11863-0

URI

https://dx.doi.org/10.1186/s12885-024-11863-0
https://hdl.handle.net/20.500.12511/12240

Collections

Diğer Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu

Creative Commons license

Except where otherwise noted, this item's license is described as Attribution 4.0 International

Full item page

Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer (BMC Cancer, (2024), 24, 1, (16), 10.1186/s12885-023-11783-5)

Files

Date

Authors

Journal Title

Journal ISSN

Volume Title

Publisher

Access Rights

DOI

Abstract

Description

Keywords

Journal or Series

WoS Q Value

Scopus Q Value

Volume

Issue

Citation

URI

Collections

Endorsement

Review

Supplemented By

Referenced By

Creative Commons license